Menta Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-373,523
| Closed | -$4.18M | – | 918 |
|
|
2017
Q3 | $4.18M | Sell |
373,523
-58,473
| -14% | -$645K | 0.61% | 3 |
|
|
2017
Q2 | $4.75M | Buy |
431,996
+35,660
| +9% | +$357K | 0.56% | 5 |
|
|
2017
Q1 | $3.88M | Buy |
396,336
+204,862
| +107% | +$2.05M | 0.38% | 43 |
|
|
2016
Q4 | $2.07M | Sell |
191,474
-8,696
| -4% | -$87K | 0.17% | 179 |
|
|
2016
Q3 | $2.05M | Buy |
200,170
+52,398
| +35% | +$571K | 0.2% | 169 |
|
|
2016
Q2 | $1.93M | Buy |
147,772
+55,416
| +60% | +$726K | 0.27% | 63 |
|
|
2016
Q1 | $1.02M | Buy |
92,356
+6,815
| +8% | +$60.6K | 0.14% | 211 |
|
|
2015
Q4 | $787K | Sell |
85,541
-26,444
| -24% | -$221K | 0.1% | 337 |
|
|
2015
Q3 | $777K | Sell |
111,985
-33,836
| -23% | -$290K | 0.12% | 307 |
|
|
2015
Q2 | $1.43M | Buy |
145,821
+77,814
| +114% | +$709K | 0.23% | 145 |
|
|
2015
Q1 | $603K | Buy |
+68,007
| New | +$542K | 0.08% | 398 |
|
|
2014
Q4 | – | Sell |
-277,968
| Closed | -$1.92M | – | 796 |
|
|
2014
Q3 | $1.92M | Buy |
+277,968
| New | +$1.67M | 0.31% | 97 |
|
|
2014
Q2 | – | Sell |
-29,068
| Closed | -$132K | – | 614 |
|
|
2014
Q1 | $132K | Buy |
29,068
+12,500
| +75% | +$60.4K | 0.04% | 345 |
|
|
2013
Q4 | $84K | Sell |
16,568
-5,484
| -25% | -$26.4K | 0.03% | 349 |
|
|
2013
Q3 | $112K | Buy |
22,052
+1,300
| +6% | +$7.24K | 0.06% | 333 |
|
|
2013
Q2 | $103K | Buy |
+20,752
| New | +$98.8K | 0.07% | 366 |
|
Menta Capital's SCLN Position: Q4 2017 in Review
Menta Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 373,523 shares — an estimated $4.18M sold.
Menta Capital first reported a position in SCLN in Q2 2013 and held it in 16 quarters. The position peaked at $4.75M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Menta Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Menta Capital sold 373,523 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $4.18M.
- Menta Capital first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 16 quarters.
- Menta Capital's Sciclone Pharmaceuticals Inc position peaked at $4.75M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Menta Capital's 13F filing for Q4 2017, filed 14 Feb 2018.